TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04570423: A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Sponsor: Spectrum Pharmaceuticals, Inc · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,247,400

Rescue Site Savings

+$831,600

Unlock Full NCT04570423 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04570423 Rescue Dossier →